International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2026
Menopausal hormone therapy prescription and ovary-sparing surgery in women with pre-menopausal endometrial cancer: a Swedish PremEnCa study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ehn Per, Ioannou Chrysanthos, Malmsten Cecilia, Holmberg Erik, Rådestad Angelique Flöter, Dahm-Kähler Pernilla, Stålberg Karin
Аннотация
OBJECTIVE: The use of ovary-sparing surgery and menopausal hormone therapy after endometrial cancer is controversial, requiring a balance between a presumed increased risk of recurrence and the well-known adverse effects of premature menopause. Studies on this topic, specifically in pre-menopausal women, are scarce and heterogeneous. This nationwide, population-based, retrospectively conducted cohort study aimed to describe the use of ovary-sparing surgery and post-treatment menopausal hormone therapy in pre-menopausal women with endometrial cancer and to analyze related factors.
METHODS: The study population comprised women aged ≤50 years diagnosed with endometrial cancer and registered in Sweden between 2010 and 2021. Data from validated Swedish registers were supplemented with manual review of medical records. Factors associated with ovary-sparing surgery were presented separately. Menopausal hormone therapy prescription was defined as at least 1 dispensing within 5 years of diagnosis. Cumulative incidence of menopausal hormone therapy prescription over 5 years was presented by sub-group. Multivariable regression was used for assessing potential factors affecting prescription patterns and included all endometrial cancer cases.
RESULTS: The study included 731 women, of whom 42 (5.7%) underwent ovary-sparing surgery. Cumulative incidence of menopausal hormone therapy prescription was 45% for women aged 18 to 39 years, 27% for those aged 40 to 44 years, and 15% for those aged 45 to 50 years (p <.001). Among women aged <40 years with low-grade endometrioid adenocarcinoma, stage I to II, 38.1% received neither ovary-sparing surgery nor menopausal hormone therapy. Multivariable regression analyses showed that younger age, body mass index <30 kg/m2, International Federation of Gynecology and Obstetrics stage I to II, and later year of diagnosis were independently associated with increased prescription of menopausal hormone therapy.
CONCLUSIONS: This study demonstrates that the use of ovary-sparing surgery and menopausal hormone therapy remains low, even in young women with low-risk endometrial cancer. Menopausal hormone therapy appears to be under-utilized, which may be attributable to inconclusive evidence regarding its impact on recurrence risk, whereas the long-term adverse consequences of premature menopause are well known.
METHODS: The study population comprised women aged ≤50 years diagnosed with endometrial cancer and registered in Sweden between 2010 and 2021. Data from validated Swedish registers were supplemented with manual review of medical records. Factors associated with ovary-sparing surgery were presented separately. Menopausal hormone therapy prescription was defined as at least 1 dispensing within 5 years of diagnosis. Cumulative incidence of menopausal hormone therapy prescription over 5 years was presented by sub-group. Multivariable regression was used for assessing potential factors affecting prescription patterns and included all endometrial cancer cases.
RESULTS: The study included 731 women, of whom 42 (5.7%) underwent ovary-sparing surgery. Cumulative incidence of menopausal hormone therapy prescription was 45% for women aged 18 to 39 years, 27% for those aged 40 to 44 years, and 15% for those aged 45 to 50 years (p <.001). Among women aged <40 years with low-grade endometrioid adenocarcinoma, stage I to II, 38.1% received neither ovary-sparing surgery nor menopausal hormone therapy. Multivariable regression analyses showed that younger age, body mass index <30 kg/m2, International Federation of Gynecology and Obstetrics stage I to II, and later year of diagnosis were independently associated with increased prescription of menopausal hormone therapy.
CONCLUSIONS: This study demonstrates that the use of ovary-sparing surgery and menopausal hormone therapy remains low, even in young women with low-risk endometrial cancer. Menopausal hormone therapy appears to be under-utilized, which may be attributable to inconclusive evidence regarding its impact on recurrence risk, whereas the long-term adverse consequences of premature menopause are well known.